Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
Status:
Terminated
Trial end date:
2020-10-15
Target enrollment:
Participant gender:
Summary
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject
crossover study of neflamapimod in early-stage Huntington disease (HD). The primary objective
is to determine whether neflamapimod can reverse hippocampal dysfunction in patients with
early-stage HD, as assessed by the virtual water-maze-test for evaluating spatial learning
and selected tests on the Cambridge Neuropsychological Test Automated Battery (CANTAB).